Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors.
The company's founder and previous CEO, Bill Love will continue his scientific leadership of Destiny in the newly created role of Chief Scientific Officer (CSO).
Destiny recently received National Institute of Health-sponsored proof-of-concept clinical study with XF-73, the lead drug from our XF drug platform.
The company is planning its first Phase IIb clinical trial, investigating XF-73 as a potential first-in-class drug for the prevention of post-surgical infections from all strains of Staphylococcus aureus.
In his new role as CSO, Bill Love will continue to focus on developing the XF platform and earlier stage projects.
The new CEO, Neil Clark, said: “The resistance to antibiotics is becoming a global issue that needs to be addressed and Destiny has a clear focus on developing effective anti-infective drugs with low resistance profiles.”
“It has a potentially valuable lead asset ready to enter Phase IIb clinical development.”
Clark joins Destiny from Ergomed, a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs.
Neil Clark joined Ergomed as Chief Financial Officer (CFO) in January 2009 and was CFO at its initial public offering in July 2014 until his move to be full time CEO of Ergomed’s PrimeVigilance business in January 2016.
Prior to Ergomed, he was as CFO and subsequently CEO at CeNeS Pharmaceuticals, a company focused on developing drugs for central nervous system disorders and pain control, until the company's sale in 2008.
Clark has spent 20 years in private and public life science companies and has a range of international experience in drug research and development, as well as licensing and partnering.
